AlexLMX / Shutterstock.com
Precision medicine is an evolving field, which takes individual variability in genes, environment, and lifestyle into account when tackling disease treatment and prevention. LSIPR reports.
As we move away from a ‘one-size-fits-all’ approach to medicine, we move towards the future: precision medicine.
This ground-breaking development also represents something else—a fundamentally different way of thinking about treatment of human suffering, says Daniel Lim, partner at the London office of Kirkland & Ellis.
“Precision medicine has the potential to yield significantly better and more reliable outcomes, with reduced side-effects, reduced waste in the healthcare system and more informed clinical decision-making,” Lim adds.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Precision medicine, genese, disease treatment, patent eligibility, Mayo v Prometheus, biotech, RCEs, diagnostic method, commercialisation, IP system
